This site requires the latest version of Macromedia Flash Player.

Cash Balance: $467.8 MM (as of 12/31/07)
Dollars invested in R&D since inception: $2,015,896,000 (as of 9/30/07)
Drugs in pipeline: 11 (plus 1 marketed)
Institutional Ownership: 92.2% (as of 2/08/08)
Number of patients enrolled in PROVE clinical trials: 1,000
Number of patients expected to enroll in TVR Phase 3 pivotal trial: 1,050
2007 Revenue: $198.7 MM
2007 R&D expense: $514.5 MM

Key Goals Achieved in 2007:

1.		Generated telaprevir Phase 2 clinical data to support transition to Phase 3
2.		Began to build commercial infrastructure for telaprevir
3.		Began clinical development of telaprevir in HCV sub-populations
4.		Began Phase 2 clinical trial of VX-770 in cystic fibrosis (CF)
5.		Began Phase 1 clinical trial of VX-809 in cystic fibrosis (CF)